Colorado Capitol Watch
border Logo hdr_right_bottom

Bill Detail: SB20-107

Return to list of bills


Title Drug Production Costs Transparency Analysis Report
Status Senate Second Reading Laid Over to 12/31/2020 - No Amendments (06/03/2020)
Bill Subjects
  • Health Care & Health Insurance
  • State Government
House Sponsors K. Mullica (D)
D. Jackson (D)
Senate Sponsors J. Ginal (D)
House Committee
Senate Committee Health and Human Services
Date Introduced 01/15/2020

The bill directs the department of health care policy and financing
(state department), or a third party with whom the department contracts,

to collect, analyze, and report prescription drug production cost data
regarding the 20 highest-cost prescription drugs per course of therapy and
the 20 highest-cost prescription drugs by volume that were purchased or
paid for by the departments of corrections, human services, personnel,
and health care policy and financing (departments) during the 2019-20
and future state fiscal years. Upon receipt of a list of the highest-cost
prescription drugs purchased or paid for by the departments, the state
department or its designated contractor, as applicable, is directed to
request from the manufacturers of the drugs on the list information
showing the basis for and components of the wholesale acquisition cost
(WAC) of each drug on the list.
The state department or its designated contractor, as applicable, is
to analyze the data received from drug manufacturers and report its
findings regarding the basis for the WAC for each prescription drug on
the list, specifying the percentage of the WAC that is attributable to each
component driving the WAC. The state department is required to provide
an annual prescription drug price transparency report by December 1,
2021, and each December 1 thereafter to specified legislative committees.
The state department and its designated contractor, as applicable, are
required to maintain the confidentiality of any proprietary information
received from a drug manufacturer, and that information is exempt from
the Colorado Open Records Act.
The executive director of the state department is authorized to
adopt rules as necessary to implement and administer the bill. A
manufacturer that fails to report the required information is subject to a
civil penalty of up to $10,000 per day.

Committee Reports
with Amendments
Full Text
Full Text of Bill (pdf) (most recent)
Fiscal Notes Fiscal Notes (02/04/2020) (most recent)  
Additional Bill Documents Bill Documents
  • Past bill versions
  • Past fiscal notes
  • Committee activity and documents
  • Bill History
Lobbyists Lobbyists
Votes House and Senate Votes
Vote Totals Vote Totals by Party
border   border
Copyright © 2019 State Capitol Watch